logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

Noninvasive research of biomarkers in clinical trials with antiangiogenics

imatge Central Grup Recerca

Scientific Team

Researchers
Margarita Garcia
Predoctoral researchers
Valentin Navarro

Introduction

The overall objective of the subgroup is related to the study of biomarkers of angiogenesis and antiangiogenic treatment approach that allows the treatment of selected patients who may be sensitive to these therapies. It is used all stages of drug development in several tumor types, since its inception to clinical use, to obtain samples from patients (mainly in blood and tumor tissue) that may clarify the mechanisms of action, set the efficacy and effectiveness and enrich the candidate population for the antiangiogenic treatment.


Research group

Tumour Angiogenesis

Research lines

. Studies of biomarkers in the clinical use context.

 

. Clinical trials with correlative studies of biomarkers


Group Publications (last three years)

 

Garcia Martin, Margarita; Perez Martin, Xavier; Camina Moncayo, Cristina; Germa Luch, Josep Ramon. 2010. [Patterns of participation in clinical trials among cancer patients: a prospective study]. Med Clin (Barc) 134 (13):591-5.

 

García M, Clopés A, Bruna J, Martínez M, Fort E, Gil M. Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manag Res. 2009 Oct 30;1:137-50.

 

Collaborations


Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, Montes A, Cuadra C, Soto-Matos A, Lebedinsky C, Alfaro V, Paz-Ares L. “Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function”. Med Oncol. 2011 Jun 10.

 

Vidal L, Magem M, Barlow C, Pardo B, Florez A, Montes A, Garcia M, Judson I, Lebedinsky C, Kaye SB, Salazar R. “Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors”. Invest New Drugs. 2010.

 

Majem M, Salazar R, Garcia M, Clopes A, Muñoz C, Pardo B, Martinez M, Cuadra C, Montes A, Mis R, Savulsky C, Ramon Germa-Lluch J. “A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors”. J Liposome Res. 2009.

 

Schoffski, P; Guillem, V; Garcia, M; Rivera, F; Tabernero, J; Cullell, M; Lopez-Martin, JA; Pollard, P; Dumez, H; del Muro, XG; Paz-Ares, L. 2009. “Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma”. MARINE DRUGS 7 (1):57-70.

Title: Estudio de los patrones clínicos y biológicos asociados a la progresión tumoral en pacientes con cáncer de colon en tratamiento con fármacos antiangiogénicos.

Financing entity: Projecte d'Investigació Clínica no comercial amb medicaments d'ús humà. Institut de Salut Carlos III, Ministeri de Sanitat i Consum. EC08/00097

Partners: IDIBELL (ICO)

Duration, from: 2009 until: 2010

Cuantía de la subvención: 51.062 euros

PI: Margarita García Martín

 

Title: ESTUDIO FASE II DE BEVACIZUMAB EN COMBINACIÓN CON CAPECITABINA Y RADIOTERAPIA COMO TRATAMIENTO PREOPERATORIO EN PACIENTES CON CÁNCER RECTAL LOCALMENTE AVANZADO RESECABLE.

Financing entity: ROCHE Farma

Partners: IDIBELL (ICO)

Duration,  from: 2009 until: 2012                     

PI: Margarita García Martín/Ramón Salazar

 

Títol del projecte: PHASE II RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED MULTICENTRE STUDY WITH BIOMARKER EVALUATION OF NEOADJUVANT EXEMESTANE IN COMBINATION WITH SUNITINIB IN POST-MENOPAUSAL WOMEN WITH HORMONE-SENSIBLE PRIMARY BREAST CANCER

Financing entity: Pfizer

Partners: IDIBELL (ICO)

Duration,  from: 2009 until: 2012                     

PI: Sonia Pernas

 

Title: PHASE II MULTI-CENTER, NON RANDOMIZED OPEN LABEL STUDY OF IPILIMUMAB (ANTI CTLA-4) ADMINISTERED IN MONOTHERAPY IN ADULT PATIENTS WITH METASTATIC UVEAL MELANOMA.

Financing entity: Bristol-Myers-Squibb

Partners: IDIBELL (ICO)

Duration,  from: 2011 until: 2014         

PI: Josep M Piulats/Margarita García

 

Title: ENSAYO CLÍNICO FASE I DE ADMINISTRACIÓN ENDOVENOSA DEL ADENOVIRUS CONDICIONALMENTE REPLICATIVO ICOVIR-5 EN PACIENTES CON MELANOMA MALIGNO LOCALMENTE AVANZADO O METASTÁSICO.

Financing entity:: Proyecto de Investigación Clínica no comercial con medicamentos de uso humano. Insituto de Salud Carlos III, Ministerio de Sanidad y Consumo.

Partners: IDIBELL (ICO)

Duration,  from: 2009 until: 2013                                 

Cuantía de la subvención: 168.000 euros

PI: Ramón Salazar

imatge personal
 

Subgroup head (PI)

Margarita Garcia
E-mail  
mgarcia@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell